Obalon Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Obalon Therapeutics generated cash of -$10,409,000, which is more than the previous year. Cash used in financing activities reached the amount of $430,000 last year. Net change in cash is therefore -$10,150,000.
Cash Flow
| 2014 | -9.90M | -7.91M | 22.18M |
|---|---|---|---|
| 2015 | -11.39M | 2.77M | 5.06M |
| 2016 | -19.36M | 6.20M | 82.78M |
| 2017 | -30.62M | -21.85M | 613K |
| 2018 | -29.43M | 19.51M | 9.99M |
| 2019 | -22.86M | 2.35M | 13.37M |
| 2020 | -10.40M | -171K | 430K |
OBLN Cash Flow Statement (2014 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 14.05M | 21.18M | 21.10M | 72.97M | 3.35M | 6.90M | 2.52M |
Operating activities | |||||||
Net income | -12.33M | -23.67M | -37.38M | -34.76M | -20.46M | -15.55M | -9.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 843K | 894K | 581K | 330K | 192K | 167K | 166K |
Stock-based compensation expense | 1.08M | 2.98M | 4.69M | 3.24M | 563K | 207K | 185K |
| Deferred income tax benefit | 1.08M | 2.98M | 4.69M | 3.24M | 563K | 207K | 185K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 285K | 585K | 3.35M | -4.22M | 0 | 96K | 83K |
Inventories | -525K | 12K | -162K | -591K | -464K | 77K | -166K |
Accounts payable | -33K | -543K | 70K | 624K | 0 | -19.53M | -19.59M |
Cash generated by operating activities | -10.40M | -22.86M | -29.43M | -30.62M | -19.36M | -11.39M | -9.90M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | -9.10M | -94.61M | -18.89M | -18.59M | -12.4M |
Investments In Property Plant And Equipment | -171K | -194K | -1.28M | -1.04M | -352K | -139K | -268K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -171K | 2.35M | 19.51M | -21.85M | 6.20M | 2.77M | -7.91M |
Financing activities | |||||||
Common Stock Issued | 0 | 23.37M | 9.82M | 429K | 67.23M | 62K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | -3M |
Cash used in financing activities | 430K | 13.37M | 9.99M | 613K | 82.78M | 5.06M | 22.18M |
Net Change In Cash | -10.15M | -7.13M | 79K | -51.86M | 69.61M | -3.54M | 4.37M |
Cash at end of period | 3.90M | 14.05M | 21.18M | 21.10M | 72.97M | 3.35M | 6.90M |
| Data source | Data source | Data source | Data source | Data source |